24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
Fax: (361)578-5500
Regular Hours: M-Fri 8am - 5pm
Every 3rd Thurs of the Month - Extended Hours Until 7 pm

Alzheimers Disease and other Cognitive Disorders
Resources
Basic Information
Introduction & Causes of Cognitive DisordersDementiaAlzheimer's DiseaseOther Cognitive DisordersDementia Coping Skills & Behavior ManagementTraumatic Brain Injury (TBI)Conclusion and Resources
More InformationLatest News
Right Amount of Sleep May Be Important in Early Alzheimer'sAHA News: Hearing Loss and the Link to DementiaDepression in Early Life May Up Dementia Risk LaterScientists Untangle Why Diabetes Might Raise Alzheimer's RiskTracking Key Protein Helps Predict Outcomes in TBI PatientsMIND Diet May Guard Against Alzheimer'sSigns of Early Alzheimer's May Be Spotted in Brain StemCould Cholesterol Help Drive Alzheimer's Disease?Common Eye Conditions Tied to Higher Risk for DementiaMultigenerational Study Finds Links Between ADHD, Dementia RiskMost Alzheimer's Patients Wouldn't Have Qualified for Controversial Drug's Trial: StudyCould Traffic Noise Raise Your Odds for Dementia?AHA News: What Are Researchers Doing to Stop Dementia?A Mentally Challenging Job Could Help Ward Off DementiaDirty Air, Higher Dementia Risk?An ALS Drug Shows Early Promise Against Alzheimer'sAHA News: Dementia Can Complicate Heart Recovery and TreatmentDeaths From Alzheimer's Far More Common in Rural AmericaCould COVID-19 Accelerate Alzheimer's Symptoms?Dementia Cases Will Nearly Triple Worldwide by 2050: StudyFDA Panel Advisor Who Panned New Alzheimer's Drug Speaks Out'Light Flash' Treatment Might Help Slow Alzheimer'sCleaning Up the Air Could Help Prevent Alzheimer'sLong-Term Outlook for Most With Serious Brain Injury Is Better Than ThoughtDrug Shows Promise in Easing Dementia-Linked PsychosisAHA News: Diabetes and Dementia Risk: Another Good Reason to Keep Blood Sugar in Check1 in 20 Cases of Dementia Occurs in People Under 65Could Menopausal Hormone Therapy Reduce Women's Odds for Dementia?Reading, Puzzles May Delay Alzheimer's by 5 Years: StudyTwo Major Health Systems Won't Administer Controversial New Alzheimer's DrugMost Marriages Survive a Spouse's Brain InjuryMedicare Mulls Coverage for Controversial Alzheimer's DrugFDA Head Asks for Investigation Into Alzheimer's Drug ApprovalNew Prescribing Instructions Tighten Use of Controversial Alzheimer's DrugMissing Teeth, Higher Odds for Dementia?AHA News: Smoking Harms the Brain, Raises Dementia Risk – But Not If You QuitHealthy Living Can Lower Your Odds for Alzheimer'sKeeping Same Nurse for All Home Health Care May Be Crucial for Dementia PatientsMost Cases of Dementia in U.S. Seniors Go Undiagnosed: StudyLilly to Seek FDA Approval for New Alzheimer's DrugCould a Type of Statin Raise Dementia Risks?Good News, Bad News From Alzheimer's Vaccine TrialPoor Sleep After Head Injury Could Point to Dementia RiskFDA Approves Alzheimer's Drug Despite Expert Panel's ObjectionsFDA Defends Approval of Controversial Alzheimer's DrugPeople of Color Have Twice the Risk of Dying After Brain Injury, Study FindsIn People With Type 1 Diabetes, Poor Blood Sugar Control Could Raise Dementia RiskThere's Been a Shift in Who's Funding Alzheimer's ResearchHealthy Living Helps Prevent Dementia, Even If It Runs in the FamilyAHA News: Is It Normal Aging or Early Signs of Dementia?
Questions and AnswersLinks
Related Topics

There's Been a Shift in Who's Funding Alzheimer's Research

HealthDay News
by Robert Preidt
Updated: May 27th 2021

new article illustration

THURSDAY, May 27, 2021 (HealthDay News) -- The U.S. government and nonprofits are replacing drug companies as the main drivers of Alzheimer's disease research, two new studies show.

The findings are from an analysis of national data by Jeffrey Cummings, a research professor at the University of Nevada, Las Vegas School of Integrated Health Sciences.

In one study, his team found that the number of Alzheimer's clinical trials supported by pharmaceutical companies decreased over the past five years, while trials supported by the federal government and public-private partnerships increased.

Drug companies have reduced early-stage research to focus mainly on late-stage clinical trials, and early-stage research is increasingly being done by academic medical centers, the investigators found.

In the last five years, there's been a 78% increase in trials by academic medical centers, primarily funded by the U.S. National Institutes of Health (NIH) and programs of the National Institute on Aging (NIA), Alzheimer's Association, and Alzheimer's Drug Discovery Foundation (ADDF), including the Alzheimer's Association's Part the Cloud initiative.

"Nonprofits and the NIH are making a huge difference in drug development for Alzheimer's and all other dementias," Cummings said in an Alzheimer's Association news release.

The second study found that while drug companies have cut back on Alzheimer's research, the total number of experimental drugs in Alzheimer's clinical trials has been relatively steady over the last five years, with a slight increase this year due to additional drugs in phase 2 studies.

The study authors also said there's an increasing number of drug targets and variety of drugs in the research pipeline, driven by phase 1 and 2 trials.

The studies were published online May 25 in Alzheimer's & Dementia: Translational Research & Clinical Interventions, a journal of the Alzheimer's Association.

Maria Carrillo, Alzheimer's Association chief science officer, said, "Alzheimer's Association funding, partnerships — including the NIA and ADDF — and advocacy for federal Alzheimer's research funding are now the primary drivers of growth in Alzheimer's clinical trials, filling the gap left by pharma's retreat, and growing and diversifying the front end of the drug pipeline."

The NIA now distributes more than $3 billion annually for Alzheimer's and dementia research, up from $500 million just a few years ago.

"This great victory is almost completely due to Alzheimer's Association legislative efforts, our grassroots advocates, and our champions in Congress," Carrillo said.

The U.S. Food and Drug Administration has not approved any new Alzheimer's drugs since 2003, but is reviewing aducanumab (Biogen) for the treatment of Alzheimer's disease. A decision is expected by June 7.

Cummings noted that "if pharma companies do not see a clear path to FDA approval, they will continue not to invest in Alzheimer's. This further highlights the importance of the decision before the FDA at this moment."

Currently, there are four FDA-approved drugs to treat the symptoms of Alzheimer's dementia, but there are no approved drugs that change the course or delay the progression of the disease.

More information

The U.S. National Institute on Aging has more about Alzheimer's treatments.

SOURCE: Alzheimer's Association, news release, May 25, 2021